ATEC Mourns Passing of Board Member Jeffrey P. Rydin

Alphatec Holdings, Inc. (Nasdaq: ATEC) has announced with profound sorrow the passing of Board Member Jeffrey P. Rydin at the age of 59, following a lengthy illness. Rydin was an integral part of ATEC, bringing nearly thirty years of expertise in the medical device and healthcare sectors, having held senior roles at notable companies such as Ellipse Technologies, NuVasive, and DePuy Spine. His journey with ATEC began in September 2016 as a Special Advisor, during which he played a pivotal role in the company's transformative sales strategies. He officially joined the Board of Directors in June 2017 and remained a trusted advisor until his final moments on November 3, 2025.

In a statement reflecting on Rydin's impact, Pat Miles, ATEC's Chairman and CEO, expressed deep sorrow over the loss of a close friend and colleague. He credited Rydin’s vision and commitment to helping build the culture and momentum at ATEC, stating, "Jeff’s early vision and commitment have been foundational to who we are today." Miles highlighted Rydin's character as a "trust-builder," emphasizing his reliability and dedication, especially in challenging times. Rydin was also cherished as a devoted husband to Melissa and a loving father to his sons, Spencer and Griffin.

As ATEC continues its mission to revolutionize spine surgery through innovation and clinical excellence, Rydin’s legacy will undoubtedly resonate within the company. The organization extends its heartfelt condolences to his family during this difficult time, reinforcing the close-knit nature of the ATEC community. For more details about ATEC and its initiatives, visit www.atecspine.com.

The recent announcement of Jeffrey P. Rydin's passing marks a significant moment in the history of Alphatec Holdings, Inc. (Nasdaq: ATEC). Mr. Rydin was not only instrumental in the company's turnaround but also served as a steady, trusted voice on its Board of Directors. His extensive experience in the medical device industry significantly contributed to ATEC's innovative strategies and sales transformations, which have positioned the company as a forward-thinking player in spine surgery.

Investors should approach this development with a balanced perspective. While the loss of a vital leader can initially stir uncertainty among stakeholders, it is important to note that ATEC has built a robust operational foundation in recent years. The strategic focus on innovation, exemplified by initiatives such as the AlphaInformatiX Platform, indicates a strong commitment to clinical excellence and competence in market leadership. This dedication can serve as a stabilizing force in the wake of leadership changes.

However, potential investors must monitor how ATEC navigates this transition. The management's ability to maintain momentum without Mr. Rydin's guidance will be critical in the coming months. Investors should keep an eye on the board's replenishment strategy and whether the company can swiftly appoint a successor who shares Rydin’s vision for the company's future.

In light of this transition, ATEC's stock may experience volatility as the market assesses the impact of Rydin's absence. Analyzing trading patterns and observing how ATEC communicates its strategic direction will be crucial for making informed investment decisions. In conclusion, while ATEC faces challenges ahead, its strong foundation in innovation and leadership vision suggests potential for resilience. Investors should remain vigilant and consider the long-term growth prospects as ATEC continues its mission in the medical device space.